Home

Welcome to the Swiss Peritoneal Cancer Group

The Swiss Peritoneal Cancer Group (SPCG) was founded in June 2013 and two years later the group was accepted as a workgroup of the Swiss Society for Visceral Surgery (Schweizerische Gesellschaft für Viszeralchirurgie, SGVC). The SPCG provides a platform for surgeons, gynecologists and medical oncologists engaged in peritoneal malignancies, cytoreduction and HIPEC.

Swiss Peritoneal Cancer Group

The aims and tasks of the SPCG are:

  • One meeting per year
  • General assembly during the congress of the Swiss Society for Surgery (Schweizerische Gesellschaft für Chirurgie, SGC) or during a congress of the Swiss Society for Visceral Surgery (Schweizerische Gesellschaft für Viszeralchirurgie, SGVC)
  • Establishing a Swiss registry for cytoreduction/HIPEC
  • Organization and realization of a regular congress on cytoreduction/HIPEC in Switzerland
  • Promotion of research in the field of cytoreduction/HIPEC

We are proud to present to you the current list of responsibilities in the SPCG.

Steffen-Thomas

Steffen Thomas
President

Adamina-Michel

Michel Adamina
Co-president

Lehmann-Kuno

Kuno Lehmann
Secretary

Frederic Ris

Fréderic Ris
Board member

Martin Hubner

Martin Hübner
Board member

Peterli-Ralph

Ralph Peterli
Board member SGVC

Swiss Society of Visceral Surgery

The society aims to promote visceral surgery in cooperation with and within the Swiss Society of Surgery (Schweizerische Gesellschaft für Chirurgie, SGC). It deals primarily with health policy issues, professional policy aspects, problems and quality of education and training as well as certification requirements. The society represents the interests of visceral surgeons in professional organizations and in collective bargaining. The group collaborates with European professional societies with the same or similar interests and can join such societies as a member.

Upcoming events

Fotolia_64395997_L

Friday, November 8th – Saturday, November 9th, 2019
Cantonal Hospital, St.Gallen/Switzerland,
Central Lecture Hall, Building 21

3rd ESDO Masterclass «Great Debates in Gastro- Intestinal Cancer Management»

Swiss Publications

publications

Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis.

Solass, W, Sempoux, C, Carr, N J, Bibeau, F, Neureiter, D, Jager, T, Di Caterino, T, Brunel, C, Klieser, E, Fristrup, C W, Mortensen, M B, Detlefsen, S.

Histopathology, (2019) 74 (7):1014-24.doi:10.1111/his.13829 PMID:30687944

 

Systemic inflammatory response after hyperthermic intraperitoneal chemotherapy (HIPEC): The perfusion protocol matters!

Roth, L, Eshmuminov, D, Laminger, F, Koppitsch, C, Schneider, M, Graf, T R, Gupta, A, Kober, F, Roka, S, Gertsch, P, Lehmann, K.

Eur J Surg Oncol, (2019) doi: 10.1016/j.ejso.2019.03.036 PMID:30954352

 

Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer.

Mertens, L S, Behrendt, M A, Mehta, A M, Stokkel, L, de Jong, J, Boot, H, Horenblas, S, van der Heijden, M S, Moonen, L M, Aalbers, A G J, Meinhardt, W, van Rhijn, B W G.

Eur J Surg Oncol, (2019) doi: 10.1016/j.ejso.2019.03.034 PMID:31003721

 

RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.

Arjona-Sanchez, A, Rodriguez-Ortiz, L, Baratti, D, Schneider, M A, Gutierrez-Calvo, A, Garcia-Fadrique, A, Tuynman, J B, Cascales-Campos, P A, Martin, V C, Morales, R, Salti, G I, Arteaga, X, Pacheco, D, Alonso-Gomez, J, Yalkin, O, Villarejo-Campos, P, Sanchez-Hidalgo, J M, Casado-Adam, A, Cosano-Alvarez, A, Rufian-Pena, S, Briceno, J.

Ann Surg Oncol, (2019) doi: 10.1245/s10434-019-07378-9 PMID:31111351

 

Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane) for peritoneal carcinomatosis – a phase I first-in-human study.

Van De Sande, L, Graversen, M, Hubner, M, Pocard, M, Reymond, M, Vaira, M, Cosyns, S, Willaert, W, Ceelen, W.

Pleura Peritoneum, (2018) 3 (2):20180112.doi:10.1515/pp-2018-0112 PMID:30911657

 

Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy.

Teixeira Farinha, H, Grass, F, Labgaa, I, Pache, B, Demartines, N, Hubner, M.

J Cancer, (2018) 9 (1):13-20.doi:10.7150/jca.21460 PMID:29290765

 

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naive upper gi-adenocarcinomas with peritoneal seeding – a phase II/III trial of the AIO/CAOGI/ACO.

Oliver Goetze, T, Al-Batran, S E, Pabst, U, Reymond, M, Tempfer, C, Bechstein, W O, Bankstahl, U, Gockel, I, Konigsrainer, A, Kraus, T, Monig, S P, Rau, B, Schwarzbach, M, Piso, P.

Pleura Peritoneum, (2018) 3 (2):20180113.doi: 10.1515/pp-2018-0113 PMID:30911658

http://www.ncbi.nlm.nih.gov/pubmed/30911658

 

The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the „Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)“, the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.

Dueckelmann, A M, Fink, D, Harter, P, Heinzelmann, V, Marth, C, Mueller, M, Reinthaller, A, Tamussino, K, Wimberger, P, Sehouli, J.

Arch Gynecol Obstet, (2018) 297 (4):837-46.doi:10.1007/s00404-018-4673-0 PMID:29356953

 

 

The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).

Bushati, M, Rovers, K P, Sommariva, A, Sugarbaker, P H, Morris, D L, Yonemura, Y, Quadros, C A, Somashekhar, S P, Ceelen, W, Dube, P, Li, Y, Verwaal, V J, Glehen, O, Piso, P, Spiliotis, J, Teo, M C C, Gonzalez-Moreno, S, Cashin, P H, Lehmann, K, Deraco, M, Moran, B, de Hingh, I.

Eur J Surg Oncol, (2018) 44 (12):1942-8.doi:10.1016/j.ejso.2018.07.003 PMID:30075978

 

Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study.

Teixeira Farinha, H, Grass, F, Kefleyesus, A, Achtari, C, Romain, B, Montemurro, M, Demartines, N, Hubner, M.

Gastroenterol Res Pract, (2017) 2017:4596176.doi 10.1155/2017/4596176 PMID:28316621

 

Major postoperative complications are a risk factor for impaired survival after CRS/HIPEC.

Schneider, M A, Eshmuminov, D, Lehmann, K.

Ann Surg Oncol, (2017) doi: 10.1245/s10434-017-5821-7 PMID:28265776

 

Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study.

Hubner, M, Teixeira Farinha, H, Grass, F, Wolfer, A, Mathevet, P, Hahnloser, D, Demartines, N.

Gastroenterol Res Pract, (2017) 2017:6852749.doi:10.1155/2017/6852749 PMID:28331493

 

Pressurized IntraPeritoneal Aerosol Chemotherapy – Practical aspects.

Hubner, M, Grass, F, Teixeira-Farinha, H, Pache, B, Mathevet, P, Demartines, N.

Eur J Surg Oncol, (2017) 43 (6):1102-9.doi: 10.1016/j.ejso.2017.03.019 PMID:28431896

http://www.ncbi.nlm.nih.gov/pubmed/28431896

 

Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis.

Grass, F, Vuagniaux, A, Teixeira-Farinha, H, Lehmann, K, Demartines, N, Hubner, M.

Br J Surg, (2017) 104 (6):669-78.doi:10.1002/bjs.10521 PMID:28407227

 

Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review.

El-Nakeep, S, Rashad, N, Oweira, H, Schmidt, J, Helbling, D, Giryes, A, Petrausch, U, Mehrabi, A, Decker, M, Abdel-Rahman, O.

Expert Rev Gastroenterol Hepatol, (2017) 11 (3):249-58.doi:10.1080/17474124.2017.1284586 PMID:28099818

To become a member

If you perform HIPEC or related procedures or if you are interested in the treatment of PSM or related procedures we would like to invite you to become a member of the group. As a member you can actively participate in the work of the SPCG and will be informed about the current developments and activities of the Group.

Since we are a workgroup of the SGVC, full membership can only be granted to members of the Swiss Society for Visceral Surgery or the Swiss Society for Surgery. Otherwise holders of an FMH-title or an FMH-equivalent title would be eligible for associate membership (“zugewandte Mitgliedschaft”).

If you are interested to become a member of the Swiss Peritoneal Cancer Group please fill out the form linked on register now and send it directly back per e-mail or to Tanja Burkard. Her contact details can be found below.

The membership fee of the Swiss Peritoneal Cancer Group will be included in the invoice for the membership fee of the Swiss Society for Visceral Surgery (SGVC).

Contact details

In case you have any questions please do not hesitate to contact Tanja Burkard who will surely help you with your requests.

Adress

Tanja Burkard
Kantonsspital St. Gallen
Klinik für Allgemein-, Viszeral-, Endokrin- und Transplantationschirurgie
Rorschacherstrasse 95
CH-9007 St. Gallen

E-Mail: tanja.burkard@kssg.ch
Phone: +41 71 494 1344

Get in contact with us